EFFICIENCY OF HUMAN PAPILLOMAVIRUS DETECTION WITH A VAGINAL DISCHARGE SELF-COLLECTION DEVICE


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective. To reveal the rate of human papillomavirus (HPV) infection among women who are in prison and to determine the prognostic value of high-risk (HR) HPV diagnosis using an Ovintip device. Subjects and methods. A total of 150 women aged 25-59years (mean age, 37.3+8.0years) who were in prison were examined. Vaginal discharge was collected using an Ovintip device and vaginal smear from the cervical canal was taken by a physician for a further HR HPV PCR test. Results. Among the 150examinees, there were HR HPV-infectedpatients (36.7%). HPV-posittve women (61.8%) were infected with several types of HR HPV. HPV16 concurrent with HPV31, 33, 39, 52, and 58 was detected in more than one third of the examinees. HPV16 prevailed in monoinfection. When the material was taken by a woman using an Ovintip device, the sensitivity and specificity of HR HPV diagnosis were 78.3 and 91.3%, respectively. Conclusion. The findings suggest that women who are in prison show a high rate of HR HPV infection. The vaginal discharge self-collection device is of high prognostic value and may be recommended for HpV detection.

Full Text

Restricted Access

About the authors

Natalia Vladimirovna Artymuk

Kemerovo State Medical Academy, Ministry of Health of Russian

Email: artymuk@gmail.ru
MD, PhD, Professor, the head of the Obstetrics and Gynecology Department Two Kemerovo 650029, Voroshilova str. 22a, Russia

Kristina Vladimirovna Marochko

Kemerovo State Medical Academy, Ministry of Health of Russian

Email: vi-nis-ka@mail.ru
postgraduate student, Obstetrics and Gynecology Department Two Kemerovo 650029, Voroshilova str. 22a, Russia

References

  1. Bosch F.X., Broker T.R., Forman D., Moscicki A.В., Gillison M.L., DoorbarJ. et al. Comprehensive control of human papillomavirus infections and related diseases. Vaccine. 2013; 31(Suppl. 7): Hl-31.
  2. Роговская С.И. Практическая колыюскопия. М.: ГЭОТАР-Медиа; 2011. 232с.
  3. Wheeler C.M., Hunt W.C., Schiffman M., Castle P.E. Human papillomavirus genotypes and the cumulative 2-years risk of cervical precancer. J. Infect. Dis. 2006; 194(9): 1291-9.
  4. Holl K, Nowakowski A.M., Powell N.r McQuggage W.G., Pirog E.C., Collas De Souza S. et al. Human papillomavirus prevalence and type-distribution in cervical glandular neoplasias: Results from a European multinational epidemiological study. Int. J. Cancer. 2015; 137(12): 2858-68.
  5. Бадалова Л.А., Роговская С.И., Гончаревская З.Л., Коган Е.А., Бебенева Т.И., Шамаракова В.М., Акопова Е. С., Сабдулаева Э.Х. Клинико- экономическая эффективность методов диагностики при CIN. Мать и дитя в Кузбассе. 2011; Спецвыпуск 1:162-5.
  6. Wright T.C., Stoler M.H., Behrens C.M., Sharma A., Zhang G., Wright T.L. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol. Oncol. 2015; 136(2): 189-97.
  7. Zhao F.H., Lewkowitz A.K., Chen F, Lin M.J., Hu S.Y., Zhang X. et al. Pooled analysis of a self-sampling HPV DNA test as a cervical cancer primary screening method. J. Natl. Cancer Inst. 2012; 104(3): 178-88.
  8. Szarewski A., Cadman L., Mallett S., Austin J., Londesborough P, Waller J. et al. Human papillomavirus testing by self-sampling: assessment of accuracy in an unsupervised clinical setting. J. Med. Screen. 2007; 14(1): 34-42.
  9. Bhatla K, Dar L., Patro A.R., Kumar P, Kriplani A., Gulati A. et al. Can human papillomavirus DNA testing of self-collected vaginal samples compare with physician-collected cervical samples and cytology for cervical cancer screening in developing countries? Cancer Epidemiol. 2009; 33(6): 446-50.
  10. Balasubramanian A., Kulasingam S.L., Baer A., Hughes J.P., Myers E.R., Mao C. et al. Accuracy and cost-effectiveness of cervical cancer screening by high-risk human papillomavirus DNA testing of self-collected vaginal samples. J. Lower Genit. Tract Dis. 2010; 14(3): 185-95.
  11. Boggan J.C., Walmer D.K, Henderson G., Chakhtoura N., McCarthy S.H., Beauvais H.J., Smith J.S. Vaginal self-sampling for human papillomavirus infection as a primary cervical cancer screening tool in a naitian population. Sex. Transm. Dis. 2015; 42(11): 655-9.
  12. Wright T. C. Jr., Denny L., Kuhn L., Pollack A., Lorincz A. HPV DNA testing of self-collected vaginal samples compared with cytologic screening to detect cervical cancer. JAMA. 2000; 283(1): 81-6.
  13. Darlin L., Borgfeldt C., Forslund О., Нёпіс E., HortlundM., DillnerJ., Kannisto P. Comparison of use of vaginal HPV self-sampling and offering flexible appointments as strategies to reach long-term non-attending women in organized cervical screening. J. Clin. Virol. 2013; 58(1): 155-60.
  14. Chou H.H., Huang H.J., Cheng H.H., Chang C.J., Yang L.Y., Huang C.C. et al. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J. Formos. Med. Assoc. 2015; Dec. 23. pii: S0929-6646( 15)00353-8. doi: 10.1016/j. jfma.2015.10.014.
  15. Марочко K.B., Артымук H.B., Фетисова ТИ. Проблемы диагностики рака шейки матки в Кемеровской области. Мать и дитя в Кузбассе. 2015; 4: 31-5.
  16. Andrae B., Kemetli L., Sparen P, Silfverdal L., Strander B., Ryd W. et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J. Natl. Cancer Inst. 2008; 100(9): 622-9.
  17. Sanner K. Significance of Human Papillomavirus (HPV) analysis for the detection of precancerous cervical lesions. Impact of self sampling. Acta Universitatis Upsaliensis. Digital Comprehensive Summaries of Uppsala Dissertations from the Faculty of Medicine 877. Uppsala, Sweden; 2013. 64p.
  18. Ondrydsovd H., Koudeldkova V, Drabek J., Vanek P, Slavkovsky R., Hajduch M. Utilization of self-sampling kits for HPV testing in cervical cancer screening - pilot study. Ceska Gynekol. 2016; 80(6): 436-43.
  19. Белокриницкая T.E., Фролова И.И., Тарбаева Д.А., Глотова Е.Ю., Золотарёва А.А., Мальцева ТВ. Ассоциации генитальных инфекций и вируса папилломы человека как конфаундинг-факторы цервикальной интраэпителиальной неоплазии. Доктор.Ру. 2015; Спецвыпуск 2: 14-7.
  20. Видяева И.Г., Уразова Л.Н., Писарева Л.Ф., Никитина Е.Г., Ховалыг С.К. Количественное определение онкогенных типов ВПЧ в популяциях женщин региона Сибири. Сибирский онкологический журнал. 2009; Приложение 2: 40-1.
  21. Rogov skaya S.I., Shabalova I.P., Mikheeva I.V., Minkina G.N., Podzolkova N.M., Shipulina O.Y. et al. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Russian Federation, the Western countries of the former Soviet Union, Caucasus region and Central Asia. Vaccine. 2013; 31(Suppl. 7): H46-58.
  22. Shipitsyna E., Zolotoverkhaya E., Kuevda D., Nasonova V., Romanyuk T, Khachaturyan A. et al. Prevalence of high-risk human papillomavirus types and cervical squamous intraepithelial lesions in women over 30 years of age in St. Petersburg, Russia. Cancer Epidemiol. 2011; 35(2): 160-4.
  23. CastellsagueX., DiazM., de Sanjose S., MunozN., HerreroR., Franceschi S. et al. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. J. Natl. Cancer Inst. 2006; 98(5): 303-15.
  24. Машкина E.B., Коваленко K.A., Сараев K.H., Лысенко О.В., Шкурат Т.П. Генодиагностика папилломавирусной инфекции у жителей Ростовской области. Валеология. 2009; 3: 21-8.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies